肺炎検査の世界市場2020-2030:機会分析・産業予測

◆英語タイトル:Pneumonia Testing Market By Types (Consumables, Analyzers), By Method (Immunodiagnostics, Molecular Diagnostics, Point of Care Testing), By Technology (Enzyme Linked Immunosorbant Assay, Immunofluoroscence, Western Blot, Polymerase Chain Reaction, Imunohistochemistry, Others), By End User (Hospitals, Diagnostic Laboratories, Homecare, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030

Allied Market Researchが発行した調査報告書(ALD22JL073)◆商品コード:ALD22JL073
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2022年4月
◆ページ数:180
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,939 ⇒換算¥878,972見積依頼/購入/質問フォーム
5 UserUSD6,654 ⇒換算¥984,792見積依頼/購入/質問フォーム
Enterprise UserUSD10,280 ⇒換算¥1,521,440見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Allied Market Research社発行の当調査レポートでは、世界の肺炎検査市場について広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、種類別(消耗品、分析装置)分析、方法別(免疫診断、分子診断、ポイントオブケア検査)分析、技術別(ELISA、免疫蛍光、ウエスタンブロット、PCR、免疫組織化学)分析、エンドユーザー別(病院、診断研究所、在宅医療、その他)分析、地域別分析、企業状況、企業情報などの内容をまとめております。当書に掲載されている企業情報には、Abott Laboratories、F.hoffman La roche、Thermofischer Inc、Hologic Inc、Biomerieux SA、Quidel Corporation、Bio Rad laborateries、Beckton and Dickinson Company、AdvanDx、Beckman Coulterなどが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の肺炎検査市場規模:種類別(消耗品、分析装置)
・世界の肺炎検査市場規模:方法別(免疫診断、分子診断、ポイントオブケア検査)
・世界の肺炎検査市場規模:技術別(ELISA、免疫蛍光、ウエスタンブロット、PCR、免疫組織化学)
・世界の肺炎検査市場規模:エンドユーザー別(病院、診断研究所、在宅医療、その他)
・世界の肺炎検査市場規模:地域別
・企業状況
・企業情報

Pneumonia is indicated as a complex infection, which affects the lower part of the respiratory tract along with the deposition of cough in the lungs. It may even occur as a consequence of an upper tract infection. Frequently, it occurs in people with weakened immunity, the geriatric population, and children. Biotechnological methods can be used for testing of pneumonia, such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR).
The major driving factors contributing to the growth of the pneumonia market are an increase in awareness regarding early diagnosis, a rise in the popularity of point of care (POC)testing, and surge in government expenditures on healthcare. However, limited detection capability, the accuracy of some of the pneumonia testing products, and regulatory & economic hurdles hamper the market growth. Some of the factors, such as an increase in the adoption of molecular diagnostic testing and untapped markets in developing countries are expected to provide lucrative growth opportunities for the pneumonia testing market.
 
The pneumonia testing market is segmented on the basis of, and region. Method, technology, type & end user. In terms of method, the market is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. By type, it is bifurcated into analyzers and consumables. Based on technology, it is categorized into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. Depending on the end-user, it is categorized into hospitals, diagnostic laboratories, home care, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the market include Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.

Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments
By Types
Consumables
Analyzers

By Method
Molecular Diagnostics
Point of Care Testing
Immunodiagnostics

By Technology
Enzyme Linked Immunosorbant Assay
Immunofluoroscence
Western Blot
Polymerase Chain Reaction
Imunohistochemistry
Others

By End User
Hospitals
Diagnostic Laboratories
Homecare
Others

By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players
Abott Laboratories
F.hoffman La roche
Thermofischer Inc
Hologic Inc
Biomerieux SA
Quidel Corporation
Bio Rad laborateries
Beckton and Dickinson Company
AdvanDx
Beckman Coulter

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PNEUMONIA TESTING MARKET, BY TYPES
4.1 Overview
4.1.1 Market size and forecast
4.2 Consumables
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Analyzers
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: PNEUMONIA TESTING MARKET, BY METHOD
5.1 Overview
5.1.1 Market size and forecast
5.2 Immunodiagnostics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Molecular Diagnostics
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Point of Care Testing
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: PNEUMONIA TESTING MARKET, BY TECHNOLOGY
6.1 Overview
6.1.1 Market size and forecast
6.2 Enzyme Linked Immunosorbent Assay
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Immunofluorescence
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Western Blot
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Polymerase Chain Reaction
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
6.6 Immunohistochemistry
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market analysis by country
6.7 Others
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market analysis by country
CHAPTER 7: PNEUMONIA TESTING MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Hospitals
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Diagnostic Laboratories
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Homecare
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
7.5 Others
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market analysis by country
CHAPTER 8: PNEUMONIA TESTING MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Types
8.2.3 North America Market size and forecast, by Method
8.2.4 North America Market size and forecast, by Technology
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Types
8.2.6.1.2 Market size and forecast, by Method
8.2.6.1.3 Market size and forecast, by Technology
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Types
8.2.6.2.2 Market size and forecast, by Method
8.2.6.2.3 Market size and forecast, by Technology
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Types
8.2.6.3.2 Market size and forecast, by Method
8.2.6.3.3 Market size and forecast, by Technology
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Types
8.3.3 Europe Market size and forecast, by Method
8.3.4 Europe Market size and forecast, by Technology
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Types
8.3.6.1.2 Market size and forecast, by Method
8.3.6.1.3 Market size and forecast, by Technology
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Types
8.3.6.2.2 Market size and forecast, by Method
8.3.6.2.3 Market size and forecast, by Technology
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 U.K.
8.3.6.3.1 Market size and forecast, by Types
8.3.6.3.2 Market size and forecast, by Method
8.3.6.3.3 Market size and forecast, by Technology
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Types
8.3.6.4.2 Market size and forecast, by Method
8.3.6.4.3 Market size and forecast, by Technology
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Types
8.3.6.5.2 Market size and forecast, by Method
8.3.6.5.3 Market size and forecast, by Technology
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Types
8.3.6.6.2 Market size and forecast, by Method
8.3.6.6.3 Market size and forecast, by Technology
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Types
8.4.3 Asia-Pacific Market size and forecast, by Method
8.4.4 Asia-Pacific Market size and forecast, by Technology
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 Japan
8.4.6.1.1 Market size and forecast, by Types
8.4.6.1.2 Market size and forecast, by Method
8.4.6.1.3 Market size and forecast, by Technology
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 China
8.4.6.2.1 Market size and forecast, by Types
8.4.6.2.2 Market size and forecast, by Method
8.4.6.2.3 Market size and forecast, by Technology
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 Australia
8.4.6.3.1 Market size and forecast, by Types
8.4.6.3.2 Market size and forecast, by Method
8.4.6.3.3 Market size and forecast, by Technology
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 India
8.4.6.4.1 Market size and forecast, by Types
8.4.6.4.2 Market size and forecast, by Method
8.4.6.4.3 Market size and forecast, by Technology
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Types
8.4.6.5.2 Market size and forecast, by Method
8.4.6.5.3 Market size and forecast, by Technology
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest Of Asia Pacific
8.4.6.6.1 Market size and forecast, by Types
8.4.6.6.2 Market size and forecast, by Method
8.4.6.6.3 Market size and forecast, by Technology
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Types
8.5.3 LAMEA Market size and forecast, by Method
8.5.4 LAMEA Market size and forecast, by Technology
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Types
8.5.6.1.2 Market size and forecast, by Method
8.5.6.1.3 Market size and forecast, by Technology
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Types
8.5.6.2.2 Market size and forecast, by Method
8.5.6.2.3 Market size and forecast, by Technology
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Types
8.5.6.3.2 Market size and forecast, by Method
8.5.6.3.3 Market size and forecast, by Technology
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Types
8.5.6.4.2 Market size and forecast, by Method
8.5.6.4.3 Market size and forecast, by Technology
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Abott Laboratories
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 F.hoffman La roche
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 Thermofischer Inc
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Hologic Inc
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Biomerieux SA
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 Quidel Corporation
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Bio Rad laborateries
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Beckton and Dickinson Company
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 AdvanDx
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Beckman Coulter
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 2. PNEUMONIA TESTING MARKET REVENUE, FOR CONSUMABLES, BY REGION , 2020-2030,($MILLION)
TABLE 3. PNEUMONIA TESTING MARKET FOR CONSUMABLES BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. PNEUMONIA TESTING MARKET REVENUE, FOR ANALYZERS, BY REGION , 2020-2030,($MILLION)
TABLE 5. PNEUMONIA TESTING MARKET FOR ANALYZERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. GLOBAL PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 7. PNEUMONIA TESTING MARKET REVENUE, FOR IMMUNODIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 8. PNEUMONIA TESTING MARKET FOR IMMUNODIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. PNEUMONIA TESTING MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 10. PNEUMONIA TESTING MARKET FOR MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. PNEUMONIA TESTING MARKET REVENUE, FOR POINT OF CARE TESTING, BY REGION , 2020-2030,($MILLION)
TABLE 12. PNEUMONIA TESTING MARKET FOR POINT OF CARE TESTING BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. GLOBAL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 14. PNEUMONIA TESTING MARKET REVENUE, FOR ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION , 2020-2030,($MILLION)
TABLE 15. PNEUMONIA TESTING MARKET FOR ENZYME LINKED IMMUNOSORBENT ASSAY BY COUNTRY, 2020-2030,($MILLION)
TABLE 16. PNEUMONIA TESTING MARKET REVENUE, FOR IMMUNOFLUORESCENCE, BY REGION , 2020-2030,($MILLION)
TABLE 17. PNEUMONIA TESTING MARKET FOR IMMUNOFLUORESCENCE BY COUNTRY, 2020-2030,($MILLION)
TABLE 18. PNEUMONIA TESTING MARKET REVENUE, FOR WESTERN BLOT, BY REGION , 2020-2030,($MILLION)
TABLE 19. PNEUMONIA TESTING MARKET FOR WESTERN BLOT BY COUNTRY, 2020-2030,($MILLION)
TABLE 20. PNEUMONIA TESTING MARKET REVENUE, FOR POLYMERASE CHAIN REACTION, BY REGION , 2020-2030,($MILLION)
TABLE 21. PNEUMONIA TESTING MARKET FOR POLYMERASE CHAIN REACTION BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. PNEUMONIA TESTING MARKET REVENUE, FOR IMMUNOHISTOCHEMISTRY, BY REGION , 2020-2030,($MILLION)
TABLE 23. PNEUMONIA TESTING MARKET FOR IMMUNOHISTOCHEMISTRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 24. PNEUMONIA TESTING MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 25. PNEUMONIA TESTING MARKET FOR OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 26. GLOBAL PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 27. PNEUMONIA TESTING MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
TABLE 28. PNEUMONIA TESTING MARKET FOR HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. PNEUMONIA TESTING MARKET REVENUE, FOR DIAGNOSTIC LABORATORIES, BY REGION , 2020-2030,($MILLION)
TABLE 30. PNEUMONIA TESTING MARKET FOR DIAGNOSTIC LABORATORIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 31. PNEUMONIA TESTING MARKET REVENUE, FOR HOMECARE, BY REGION , 2020-2030,($MILLION)
TABLE 32. PNEUMONIA TESTING MARKET FOR HOMECARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 33. PNEUMONIA TESTING MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 34. PNEUMONIA TESTING MARKET FOR OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 35. PNEUMONIA TESTING MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 36. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 37. NORTH AMERICA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 38. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 39. NORTH AMERICA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 40. NORTH AMERICA PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 41. U.S. PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 42. U.S. PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 43. U.S. PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 44. U.S. PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 45. CANADA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 46. CANADA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 47. CANADA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 48. CANADA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 49. MEXICO PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 50. MEXICO PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 51. MEXICO PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 52. MEXICO PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 53. EUROPE PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 54. EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 55. EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 56. EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 57. EUROPE PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 58. GERMANY PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 59. GERMANY PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 60. GERMANY PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 61. GERMANY PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 62. FRANCE PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 63. FRANCE PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 64. FRANCE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 65. FRANCE PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 66. U.K. PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 67. U.K. PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 68. U.K. PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 69. U.K. PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 70. ITALY PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 71. ITALY PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 72. ITALY PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 73. ITALY PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 74. SPAIN PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 75. SPAIN PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 76. SPAIN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 77. SPAIN PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 78. REST OF EUROPE PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 79. REST OF EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 80. REST OF EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 81. REST OF EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 82. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 83. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 84. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 85. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 86. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 87. JAPAN PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 88. JAPAN PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 89. JAPAN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 90. JAPAN PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 91. CHINA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 92. CHINA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 93. CHINA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 94. CHINA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 95. AUSTRALIA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 96. AUSTRALIA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 97. AUSTRALIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 98. AUSTRALIA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 99. INDIA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 100. INDIA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 101. INDIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 102. INDIA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 103. SOUTH KOREA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 104. SOUTH KOREA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 105. SOUTH KOREA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 106. SOUTH KOREA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 107. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 108. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 109. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 110. REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 111. LAMEA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 112. LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 113. LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 114. LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 115. LAMEA PNEUMONIA TESTING MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 116. BRAZIL PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 117. BRAZIL PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 118. BRAZIL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 119. BRAZIL PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 120. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 121. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 122. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 123. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 124. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 125. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 126. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 127. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 128. REST OF LAMEA PNEUMONIA TESTING MARKET, BY TYPES, 2020-2030,($MILLION)
TABLE 129. REST OF LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2020-2030,($MILLION)
TABLE 130. REST OF LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2020-2030,($MILLION)
TABLE 131. REST OF LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 132.ABOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 133.ABOTT LABORATORIES: OPERATING SEGMENTS
TABLE 134.ABOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 135.ABOTT LABORATORIES: NET SALES,
TABLE 136.ABOTT LABORATORIES: KEY STRATERGIES
TABLE 137.F.HOFFMAN LA ROCHE: COMPANY SNAPSHOT
TABLE 138.F.HOFFMAN LA ROCHE: OPERATING SEGMENTS
TABLE 139.F.HOFFMAN LA ROCHE: PRODUCT PORTFOLIO
TABLE 140.F.HOFFMAN LA ROCHE: NET SALES,
TABLE 141.F.HOFFMAN LA ROCHE: KEY STRATERGIES
TABLE 142.THERMOFISCHER INC: COMPANY SNAPSHOT
TABLE 143.THERMOFISCHER INC: OPERATING SEGMENTS
TABLE 144.THERMOFISCHER INC: PRODUCT PORTFOLIO
TABLE 145.THERMOFISCHER INC: NET SALES,
TABLE 146.THERMOFISCHER INC: KEY STRATERGIES
TABLE 147.HOLOGIC INC: COMPANY SNAPSHOT
TABLE 148.HOLOGIC INC: OPERATING SEGMENTS
TABLE 149.HOLOGIC INC: PRODUCT PORTFOLIO
TABLE 150.HOLOGIC INC: NET SALES,
TABLE 151.HOLOGIC INC: KEY STRATERGIES
TABLE 152.BIOMERIEUX SA: COMPANY SNAPSHOT
TABLE 153.BIOMERIEUX SA: OPERATING SEGMENTS
TABLE 154.BIOMERIEUX SA: PRODUCT PORTFOLIO
TABLE 155.BIOMERIEUX SA: NET SALES,
TABLE 156.BIOMERIEUX SA: KEY STRATERGIES
TABLE 157.QUIDEL CORPORATION: COMPANY SNAPSHOT
TABLE 158.QUIDEL CORPORATION: OPERATING SEGMENTS
TABLE 159.QUIDEL CORPORATION: PRODUCT PORTFOLIO
TABLE 160.QUIDEL CORPORATION: NET SALES,
TABLE 161.QUIDEL CORPORATION: KEY STRATERGIES
TABLE 162.BIO RAD LABORATERIES: COMPANY SNAPSHOT
TABLE 163.BIO RAD LABORATERIES: OPERATING SEGMENTS
TABLE 164.BIO RAD LABORATERIES: PRODUCT PORTFOLIO
TABLE 165.BIO RAD LABORATERIES: NET SALES,
TABLE 166.BIO RAD LABORATERIES: KEY STRATERGIES
TABLE 167.BECKTON AND DICKINSON COMPANY: COMPANY SNAPSHOT
TABLE 168.BECKTON AND DICKINSON COMPANY: OPERATING SEGMENTS
TABLE 169.BECKTON AND DICKINSON COMPANY: PRODUCT PORTFOLIO
TABLE 170.BECKTON AND DICKINSON COMPANY: NET SALES,
TABLE 171.BECKTON AND DICKINSON COMPANY: KEY STRATERGIES
TABLE 172.ADVANDX: COMPANY SNAPSHOT
TABLE 173.ADVANDX: OPERATING SEGMENTS
TABLE 174.ADVANDX: PRODUCT PORTFOLIO
TABLE 175.ADVANDX: NET SALES,
TABLE 176.ADVANDX: KEY STRATERGIES
TABLE 177.BECKMAN COULTER: COMPANY SNAPSHOT
TABLE 178.BECKMAN COULTER: OPERATING SEGMENTS
TABLE 179.BECKMAN COULTER: PRODUCT PORTFOLIO
TABLE 180.BECKMAN COULTER: NET SALES,
TABLE 181.BECKMAN COULTER: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.PNEUMONIA TESTING MARKET SEGMENTATION
FIGURE 2.PNEUMONIA TESTING MARKET,2020-2030
FIGURE 3.PNEUMONIA TESTING MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.PNEUMONIA TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.PNEUMONIA TESTING MARKET,BY TYPES,2020(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CONSUMABLES PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANALYZERS PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 15.PNEUMONIA TESTING MARKET,BY METHOD,2020(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IMMUNODIAGNOSTICS PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF POINT OF CARE TESTING PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 19.PNEUMONIA TESTING MARKET,BY TECHNOLOGY,2020(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ENZYME LINKED IMMUNOSORBENT ASSAY PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF IMMUNOFLUORESCENCE PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF WESTERN BLOT PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF POLYMERASE CHAIN REACTION PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF IMMUNOHISTOCHEMISTRY PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 26.PNEUMONIA TESTING MARKET,BY END USER,2020(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC LABORATORIES PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF HOMECARE PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHERS PNEUMONIA TESTING MARKET,2020-2030(%)
FIGURE 31.PNEUMONIA TESTING MARKET BY REGION,2020
FIGURE 32.U.S. PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 33.CANADA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 34.MEXICO PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 35.GERMANY PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 36.FRANCE PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 37.U.K. PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 38.ITALY PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 39.SPAIN PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 40.REST OF EUROPE PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 41.JAPAN PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 42.CHINA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 43.AUSTRALIA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 44.INDIA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 45.SOUTH KOREA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 46.REST OF ASIA PACIFIC PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 47.BRAZIL PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 48.SAUDI ARABIA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 49.SOUTH AFRICA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 50.REST OF LAMEA PNEUMONIA TESTING MARKET,2020-2030($MILLION)
FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 55.COMPETITIVE DASHBOARD
FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 57.ABOTT LABORATORIES.: NET SALES ,($MILLION)
FIGURE 58.F.HOFFMAN LA ROCHE.: NET SALES ,($MILLION)
FIGURE 59.THERMOFISCHER INC.: NET SALES ,($MILLION)
FIGURE 60.HOLOGIC INC.: NET SALES ,($MILLION)
FIGURE 61.BIOMERIEUX SA.: NET SALES ,($MILLION)
FIGURE 62.QUIDEL CORPORATION.: NET SALES ,($MILLION)
FIGURE 63.BIO RAD LABORATERIES.: NET SALES ,($MILLION)
FIGURE 64.BECKTON AND DICKINSON COMPANY.: NET SALES ,($MILLION)
FIGURE 65.ADVANDX.: NET SALES ,($MILLION)
FIGURE 66.BECKMAN COULTER.: NET SALES ,($MILLION)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肺炎検査の世界市場2020-2030:機会分析・産業予測(Pneumonia Testing Market By Types (Consumables, Analyzers), By Method (Immunodiagnostics, Molecular Diagnostics, Point of Care Testing), By Technology (Enzyme Linked Immunosorbant Assay, Immunofluoroscence, Western Blot, Polymerase Chain Reaction, Imunohistochemistry, Others), By End User (Hospitals, Diagnostic Laboratories, Homecare, Others): Global Opportunity Analysis and Industry Forecast, 2020-2030)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆